Probiotic Intervention for Occasional Constipation
Launched by PROBI AB · May 30, 2024
Trial Information
Current as of February 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Males and females aged 18 - 65 years
- • With occasional constipation
- • Agrees to maintain current lifestyle habits
- • Healthy
- • Provided voluntary, written, informed consent to participate in the study
- Exclusion Criteria:
- • Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
- • Allergy, sensitivity, or intolerance to study products or clinical assessment materials
- • Chronic constipation
- • Current or history of significant diseases or abnormalities of the gastrointestinal tract (examples (include but are not limited to atrophic gastritis, celiac disease, gluten intolerance/sensitivity, inflammatory bowel disease)
- • Unstable metabolic disease or chronic diseases
- • Unstable hypertension.
- • Type I or Type II diabetes, cancer
- • Significant cardiovascular event in the past 6 months. History of or current diagnosis with kidney and/or liver diseases
- • Self-reported confirmation of current or pre-existing thyroid condition.
- • Individuals with an autoimmune disease or are immune compromised
- • Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis, blood/bleeding disorders
- • Any other condition or lifestyle factor, that may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
About Probi Ab
Probi AB is a leading biotechnology company specializing in the development and commercialization of probiotic products for health and wellness. With a strong emphasis on research and innovation, Probi AB leverages its expertise in microbiome science to create evidence-based probiotic solutions that support digestive health, immune function, and overall well-being. The company collaborates with academic institutions and industry partners to conduct rigorous clinical trials, ensuring the efficacy and safety of its products. Committed to advancing scientific knowledge and improving consumer health, Probi AB is at the forefront of probiotic research and development.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, Ontario, Canada
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0